Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clobetasol propionate + eosin
- Development stage
- Unknown
- Lead developer
- Fougera Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Clobetasol propionate + eosin is a combination topical treatment primarily used for psoriasis. Clobetasol propionate is a super potent synthetic corticosteroid that reduces inflammation, suppresses immune response, and inhibits cell proliferation. When combined with eosin, it has shown significant efficacy in treating psoriasis, particularly when used on alternate days with eosin plus cade oil.
02
Targets
IKZF4 (Ikaros family zinc finger protein 4)GR (Glucocorticoid receptor)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)
Beyond the preview
Go deeper on clobetasol propionate + eosin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clobetasol propionate + eosin.